Analysts Expect Zynerba Pharma (ZYNE) Stock to Rise 66%; Rated Strong Buy

 

Zynerba Pharmaceuticals Inc (ZYNE) stock is up nearly 21% this week and more than 69% over the last 30 days. ZYNE stock is down -5.60% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives ZYNE stock an overall score of 83 out of a possible 100.

That score is primarily influenced by a long-term technical score of 99. ZYNE’s score also includes a short-term technical score of 90. The fundamental score for ZYNE is 60. In addition to the average rating from Wall Street analysts, ZYNE stock has a mean target price of $16.30. This means analysts expect the stock to gain 66.67% over the next 12 months.

Click Here to get the full Stock Score Report on Zynerba Pharmaceuticals Inc (ZYNE).

What’s Happening with ZYNE Stock Today

Zynerba Pharmaceuticals Inc (ZYNE) stock is higher by 2.93% while the S&P 500 is higher by 0.92% as of 12:26 PM on Tuesday, Apr 23. ZYNE is higher by $0.28 from the previous closing price of $9.50 on volume of 1,833,621 shares. Over the past year the S&P 500 is higher by 9.90% while ZYNE is down -5.60%. ZYNE lost -$2.61 per share in the over the last 12 months.

Symbols: ZYNE

You May Also Like